Results 21 to 30 of about 118,238 (222)
Lipometabolic side-effects of three ritonavir-boosted double protease inhibitor regimens without reverse transcriptase inhibitors [PDF]
Poster presentation: Purpose of the study To compare the lipometabolic profiles of three double-boosted protease inhibitor (PI) regimens at standard dose, containing saquinavir and ritonavir in combination with lopinavir (LOPSAQ), atazanavir (ATSAQ) or ...
Bickel, Markus +8 more
core +1 more source
Ipecac alkaloids are secondary metabolites produced in the medicinal plant Psychotria ipecacuanha. Emetine is the main alkaloid of ipecac and one of the active compounds in syrup of Ipecac with emetic property. Here we evaluated emetine’s potential as an
Ana Luiza Chaves Valadão +6 more
doaj +1 more source
HIV-1 reverse transcriptase is one of the most attractive targets for the treatment of AIDS. However, the rapid emergence of drug-resistant strains and unsatisfactory drug-like properties seriously limit the clinical application of HIV-1 non-nucleoside ...
Xiangyi Jiang +17 more
doaj +1 more source
Nucleoside reverse transcriptase inhibitors and HIV mutagenesis [PDF]
Potent antiretroviral therapy (ART) of HIV-1 infection with anti-retroviral drugs consisting of nucleoside reverse transcriptase inhibitors(NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs)and protease inhibitors (PIs) has dramatically reduced the rate ofHIV- and AIDS-related morbidity and mortality. The lack of patientcompliance to drug
Nancy A, Jewell +3 more
openaire +2 more sources
Introduction: The present study aimed to report the prevalent HIV-1 drug-resistant mutations in patients with HIV-1 alone and tuberculosis (TB) coinfection alone to improve our understanding of the mutation patterns and aid treatment decisions.
Nawaid Hussain Khan PhD +5 more
doaj +1 more source
Natural polymorphisms of HIV type 2 pol sequences from drug-naive individuals [PDF]
Until today, the susceptibility of human immunodeficiency virus type 2 (HIV-2) to protease and nucleosidic reverse-transcriptase inhibitors (PI and NRTI, respectively) has not been clearly documented. In this report we studied HIV-2 proviral sequences (n
Esteves, A. +6 more
core +1 more source
HIV-1 and HIV-2 Reverse Transcriptases: Different Mechanisms of Resistance to Nucleoside Reverse Transcriptase Inhibitors [PDF]
ABSTRACT As anti-HIV therapy becomes more widely available in developing nations, it is clear that drug resistance will continue to be a major problem. The related viruses HIV-1 and HIV-2 share many of the same resistance pathways to nucleoside reverse transcriptase inhibitors (NRTIs).
Paul L, Boyer +2 more
openaire +2 more sources
Monitoring genetic diversity and drug resistance mutations (DRMs) is critical for understanding HIV epidemiology. Here, we report HIV-1 genetic diversity and DRMs in blood samples from 42 HIV-positive pregnant women naive to antiretroviral therapy (ART),
Cruz S Sebastião +8 more
doaj +1 more source
Exploring the role of the α-carboxyphosphonate moiety in the HIV-RT activity of α-carboxy nucleoside phosphonates [PDF]
As α-carboxy nucleoside phosphonates (α-CNPs) have demonstrated a novel mode of action of HIV-1 reverse transcriptase inhibition, structurally related derivatives were synthesized, namely the malonate 2, the unsaturated and saturated bisphosphonates 3 ...
Arnold, Eddy +6 more
core +1 more source
Background Acquired immunodeficiency syndrome (AIDS), which is caused by the human immunodeficiency virus (HIV), is an immunosuppressive disease that results in life-threatening opportunistic infections.
Han Huamin, He Wen, Wang Wei, Gao Bin
doaj +1 more source

